The safety and efficacy of acute graft‐versus‐host disease prophylaxis with a higher target blood concentration of cyclosporine around 500 ng/mL
Authors:
- 20 August 2013
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 27 (5) , 749-756
Abstract
Cyclosporine (CsA) is the most widely used immunosuppressive agent for the prevention of acute graft‐versus‐host disease (GVHD). In a previous report, the incidence of acute GVHD was decreased by increasing the target blood concentration of CsA during a continuous infusion from 300 to 500 ng/mL without excessive toxicities. To confirm these results, we retrospectively analyzed 69 patients who received a continuous infusion of CsA at a higher target CsA level between 450 and 550 ng/mL (CsA500 group) and compared the clinical outcome with 29 patients who received CsA with a lower target concentration between 250 and 350 ng/mL (CsA300 group). The target concentration was determined based on the status of background diseases. Multivariate analysis revealed that the incidence of grade III‐IV acute GVHD was significantly lower in the CsA500 group, although the incidence of grade II‐IV acute GVHD was not different. Toxicities were equivalently observed between the two groups. Concomitant administration of voriconazole or itraconazole and higher hematocrit were identified as independent significant factors for higher concentration/dose ratio of CsA. The average dose of CsA to maintain CsA level around 500 ng/mL was higher compared with the previous study (3.4 mg/kg vs. 2.7 mg/kg at three wk), probably due to the difference in measuring method of CsA concentration. We conclude that continuous infusion of CsA with a target level between 450 and 550 ng/mL is a feasible and effective GVHD prophylaxis, but caution should be paid for the difference in measuring method.Keywords
This publication has 14 references indexed in Scilit:
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipientsBone Marrow Transplantation, 2009
- Decreased incidence of acute graft‐versus‐host disease by continuous infusion of cyclosporine with a higher target blood levelAmerican Journal of Hematology, 2007
- Pharmacokinetic modelling of the interaction between St John’s wort and ciclosporin ABritish Journal of Clinical Pharmacology, 2006
- Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusionBone Marrow Transplantation, 2004
- A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT)Bone Marrow Transplantation, 1997
- Comparison of a Monoclonal Antibody Fluorescent Polarization Immunoassay with Monoclonal Antibody Radioimmunoassay for Cyclosporin Determination in Whole BloodTherapeutic Drug Monitoring, 1992
- IMMUNOLOGIC RECOVERY IN THALASSEMIC MARROW GRAFT RECIPIENTS FOLLOWING HIGH-DOSE BUSULFAN AND CYCLOPHOSPHAMIDETransplantation, 1988
- Serum Cyclosporine Concentration and Risk of Acute Graft-versus-Host Disease after Allogeneic Marrow TransplantationNew England Journal of Medicine, 1988
- Clinical Pharmacokinetics of CyclosporinClinical Pharmacokinetics, 1986